Radionuclide News and Research

RSS

New program sets out to change the European landscape for emerging medical radionuclides

The European medical radionuclides programme sets out to substantially change the European landscape for novel and emerging medical radionuclides.

23 Sep 2021

NFCR announces winners of 2021 Salisbury Award Competition

The National Foundation for Cancer Research (NFCR) announced winners of the 2021 Salisbury Award Competition for Entrepreneurial Translational Research, selected from among eight semi-finalists after pitch presentations in front of a judging committee consisting of prominent cancer research scientists, clinicians, early-stage investors and business leaders.

26 May 2021

New treatment for late-stage neuroendocrine tumors found to be more effective and less toxic

A new treatment for late-stage neuroendocrine tumors (NETs) has been found to be more effective and have fewer side effects than the current standard of care, according to research published in the March issue of The Journal of Nuclear Medicine.

22 Mar 2021

New system may offer improved options for cancer treatment

Improved options for cancer treatment are on the way, thanks to a new system developed at Los Alamos National Laboratory for producing alpha-emitting medical radioisotopes intended to target and overpower diseased tissue while sparing the healthy tissue around it.

11 Mar 2021

PRRT technology may offer new treatment approaches for neuroendocrine tumors

Neuroendocrine tumors are cancers that begin in specialized cells called neuroendocrine cells. These cells have traits similar to those of nerve cells and hormone-producing cells.

9 Mar 2021

Metal-containing radiopharmaceuticals could improve access to diagnostic imaging of AD

A team of researchers from the Laboratory of Biophysics at NUST MISIS, Lomonosov Moscow State University and D. Mendeleev University of Chemical Technology of Russia has summarized metal-containing diagnostic agents for positron emission tomography (PET), magnetic resonance imaging (MRI), and single-photon emission computed tomography (SPECT) imaging of Alzheimer's disease (AD).

9 Feb 2021

Study shows efficacy of radionuclide therapy–immunotherapy combination in prostate cancer model

A combination of radionuclide therapy and immunotherapy has proven successful in slowing the progression of prostate cancer and increasing survival time, according to new research published in the February issue of The Journal of Nuclear Medicine.

8 Feb 2021

Study investigates effect of anti-CD45 RIT lymphodepletion on immune cell types

Oncotarget recently published "Targeted lymphodepletion with a CD45-directed antibody radioconjugate as a novel conditioning regimen prior to adoptive cell therapy" which reported that Chimeric antigen receptor T cell therapies, and adoptive cell therapy in general, represent one of the most promising anti-cancer strategies.

12 Jan 2021

Researchers develop α-emitting cancer therapy using a novel drug targeting LAT1

A cancer-specific L-type amino acid transporter 1 (LAT1) is highly expressed in cancer tissues.

4 Jan 2021

NET study: New theranostic approach effective in reducing tumor volume and extending lifespan

A pair of copper radionuclides that target the somatostatin receptor overexpressed in neuroendocrine tumors has proven successful in identifying tumors and improving survival.

16 Dec 2020

New nanomedicine is efficient and less aggressive than conventional prostate cancer therapy

Prostate cancer is the most common type of cancer among European men; its incidence surpasses 100 cases per 100,000 people.

15 Sep 2020

Simple process could enhance personalization of cancer therapy

Researchers have developed a simplified process that could enhance personalization of cancer therapy based on a single nuclear medicine scan.

12 Aug 2020

New alpha-radioimmunotherapy for multiple myeloma shows promise in preclinical study

A new alpha-radioimmunotherapy, 212Pb-anti-CD38, has proven effective in preventing tumor growth and increasing survival in multiple myeloma tumor-bearing mice, according to new research published in the July issue of the Journal of Nuclear Medicine. Given the long half-life, central production and worldwide distribution of 212Pb-anti-CD38, researchers have determined that the α-radioimmunotherapy is not only effective but also clinically feasible as a multiple myeloma treatment.

6 Aug 2020

New radiopharmaceutical shows excellent imaging performance in tumor detection

For neuroendocrine cancer patients with liver metastases, a new radiopharmaceutical, 68Ga-DOTA-JR11, has shown excellent imaging performance in tumor detection, staging, and restaging, providing important information to guide treatment.

26 Jun 2020

New technique reveals potentially treatable mutations in subset of prostate cancer patients

Prostate cancer patients who do not respond well to PSMA-targeted therapy often have potentially treatable mutations in their DNA damage-repair genes, according to research published in the May issue of The Journal of Nuclear Medicine.

20 May 2020

Molecular imaging can help identify treatment response in neuroendocrine tumor patients

A new proof-of-concept study published in the May issue of The Journal of Nuclear Medicine has demonstrated that molecular imaging can be used for identifying early response to 177Lu-DOTATATE treatment in neuroendocrine tumor patients.

14 May 2020

Researchers develop a unique radiochemical synthesis approach for treating cancer

Radiolabeled molecules, so-called radiotracers, help nuclear physicians to detect and precisely target tumors, which are often developing due to pathological changes in metabolic processes.

7 Apr 2020

The Pancreatic Cancer Collective awards additional funding of $16 million for new therapies

The Pancreatic Cancer Collective, the strategic partnership of Lustgarten Foundation and Stand Up To Cancer, has awarded additional funding of up to $16 million to four teams of top researchers as part of its "New Therapies Challenge Grants," the American Association for Cancer Research, Scientific Partner of SU2C, announced today.

5 Mar 2020

New radiotracer to improve image-based differential diagnostics of Parkinson’s disease

An interdisciplinary team from the Institute of Radiopharmaceutical Cancer Research headed by Prof. Peter Brust has won HZDR's (Helmholtz-Zentrum Dresden-Rossendorf) third Innovation Contest.

27 Feb 2020

New radiopharmaceutical could aid in more accurate diagnosis of neuroendocrine tumor metastases

The newly developed [55Co]55Co-DOTATATE imaging agent has emerged as a more accurate and sensitive radiopharmaceutical to aid in the diagnosis of neuroendocrine tumor metastases.